Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors
Soren Charmsaz, … , Elizabeth Jaffee, Won Jin Ho
Soren Charmsaz, … , Elizabeth Jaffee, Won Jin Ho
Published March 9, 2021
Citation Information: JCI Insight. 2021;6(7):e143283. https://doi.org/10.1172/jci.insight.143283.
View: Text | PDF
Resource and Technical Advance Immunology Oncology

A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors

  • Text
  • PDF
Abstract

With the advent of cancer immunology, mass cytometry has been increasingly employed to characterize the responses to cancer therapies and the tumor microenvironment (TME). One of its most notable applications is efficient multiplexing of samples into batches by dedicating a number of metal isotope channels to barcodes, enabling robust data acquisition and analysis. Barcoding is most effective when markers are present in all cells of interest. While CD45 has been shown to be a reliable marker for barcoding all immune cells in a given sample, a strategy to reliably barcode mouse cancer cells has not been demonstrated. To this end, we identified CD29 and CD98 as markers widely expressed by commonly used mouse cancer cell lines. We conjugated anti-CD29 and anti-CD98 antibodies to cadmium or indium metals and validated their utility in 10-plex barcoding of live cells. Finally, we established a potentially novel barcoding system incorporating the combination of CD29, CD98, and CD45 to multiplex 10 tumors from s.c. MC38 and KPC tumor models, while successfully recapitulating the known contrast in the PD1-PDL1 axis between the 2 models. The ability to barcode tumor cells along with immune cells empowers the interrogation of the tumor-immune interactions in mouse TME studies.

Authors

Soren Charmsaz, Nicole Gross, Elizabeth Jaffee, Won Jin Ho

×

Figure 5

Comparison of PDL1-PD1 axis between KPC and MC38 tumor models.

Options: View larger image (or click on image) Download as PowerPoint
Comparison of PDL1-PD1 axis between KPC and MC38 tumor models.
(A) Repre...
(A) Representative UMAPs for the tumor model, CD45, CD11b, F4/80, PDL1, and PD1 expression. (B) Violin plots comparing the expression levels of PDL1 and PD1 in specific cell type clusters with annotations of median fold difference (KPC/MC38) and FDR-adjusted P values by edgeR: ***P < 0.005, *P < 0.05. Number of cells for each comparison of KPC versus MC38: TAM1, 55,607 versus 519,369; TAM2, 45,595 versus 122,957; TAM3, 373,020 versus 26,437; Tumor1, 511,692 versus 396,897; Tumor2, 32,692 versus 107,499; CD4, 30,656 versus 3229; CD8 N, 38,463 versus 6,339; CD8 PD1+, 102,213 versus 17,319; Treg, 23,766 versus 7928. CD8 N, naive CD8+ T cells; TAM, tumor-associated macrophages.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts